StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)

Stock analysts at StockNews.com assumed coverage on shares of OpGen (NASDAQ:OPGN) in a report released on Thursday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Trading Down 2.0 %

Shares of OPGN stock opened at $0.48 on Thursday. The firm’s fifty day moving average price is $0.57 and its two-hundred day moving average price is $0.49. OpGen has a 1 year low of $0.17 and a 1 year high of $3.84. The firm has a market capitalization of $6.08 million, a P/E ratio of -0.07 and a beta of -0.56.

Institutional Trading of OpGen

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp acquired a new position in shares of OpGen, Inc. (NASDAQ:OPGN) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned approximately 2.63% of OpGen as of its most recent SEC filing. Institutional investors and hedge funds own 2.68% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.